Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus tremelimumab in advanced thyroid carcinoma
2018-001066-42Phase 2Active
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Nov 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of durvalumab and tremelimumab in well-differentiated thyroid cancer (WDTC), papillary thyroid cancer (PTC), poorly differentiated thyroid carcinoma (PDTC) and 1 more (3 cohorts), sponsored by Spanish Group of Neuroendocrine Tumors. Primary endpoints: Progression-free survival rate at 6 months (DTC and MTC cohorts) and Overall response rate by irRECIST and RECIST. Started Nov 2018; status: active.
02
Drugs
durvalumabtremelimumab
03
Conditions
well-differentiated thyroid cancer (WDTC)papillary thyroid cancer (PTC)poorly differentiated thyroid carcinoma (PDTC)Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on 2018-001066-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001066-42.